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Abstract
Background: Growth hormone (GH) plays an incompletely understood role in the development
of the central nervous system (CNS). In this study, we use transgenic mice expressing a growth
hormone antagonist (GHA) to explore the role of GH in regulating postnatal brain, spinal cord and
body growth into adulthood. The GHA transgene encodes a protein that inhibits the binding of GH
to its receptor, specifically antagonizing the trophic effects of endogenous GH.
Results: Before 50 days of postnatal age, GHA reduces spinal cord weight more than brain weight,
but less than body weight. Thereafter, GHA ceases to inhibit the increase in body weight, which
approaches control levels by day 150. In contrast, GHA continues to act on the CNS after day 50,
reducing spinal cord growth to a greater extent and for a longer duration than brain growth.
Conclusions: Judging from its inhibition by GHA, GH differentially affects the magnitude, velocity
and duration of postnatal growth of the brain, spinal cord and body. GH promotes body
enlargement more than CNS growth early in postnatal life. Later, its CNS effects are most obvious
in the spinal cord, which continues to exhibit GH dependence well into adulthood. As normal CNS
growth slows, so does its inhibition by GHA, suggesting that reduced trophic effects of GH
contribute to the postnatal slowing of CNS growth. GHA is a highly useful tool for studying the
role of endogenous GH on organ-specific growth during aging.
Background
The mammalian CNS acquires most of its mature size
after birth. Human brain weight increases 3–4 fold
between birth and maturity [1], while the spinal cord
enlarges about 10 times postnatally [2]. After maturity is
reached, the human brain declines in size by approxi-
mately 2% each decade [1], while spinal cord size declines
approximately 3% per decade [3].
Growth hormone helps to drive postnatal CNS growth.
Evidence for its role comes from several sources, including
reduced brain size in human GH deficiency disorders and
in experimental animals [4,5]. Transgenic mice have been
especially useful in demonstrating the role of GH in CNS
growth [6-9]. Strong evidence for a trophic role of GH in
brain growth has come from transgenic mice whose soma-
totropes were selectively destroyed after birth by the
expression of a GH promoter-driven diphtheria toxin
transgene [6,10,11]. Additional evidence for trophic
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effects of GH on the CNS was obtained from transgenic
mice that overexpress GH. Our laboratory previously
found a 12% increase in mean brain weight in adult mice
expressing excess GH (GH+) [7], consistent with other
studies showing slight brain enlargement in such animals
[8,9].
There is much less information about the effects of GH on
the spinal cord than on the brain. We previously reported
a mean increase of 35% in spinal cord weight in GH+
mice, indicating that the spinal cord has a much greater
capacity for GH-dependent, supranormal growth than
does the brain [7]. There is no information about the
effects of reduced endogenous GH action on spinal cord
size in transgenic mice. To examine further the role of GH
in postnatal spinal cord, brain and body growth, we have
utilized transgenic mice expressing GHA, an antagonist of
human GH that inhibits the binding of endogenous GH
to its receptor [12]. We find evidence for differential
trophic effects of GH on the magnitude, rate and duration
of postnatal growth of the body, brain and spinal cord in
GHA transgenic mice, providing strong evidence for
organ-specific dependence on GH during early postnatal
life and adulthood.
Results
Postnatal body weight increase in WT(wild-type) mice
Body weights differed significantly (p < 0.05 or less)
between males and females in WT mice at all ages. A
period of early, rapid body growth was observed in WT
mice until about day 50 (Fig. 1, solid lines). Between the
age of weaning (day 21) and day 50, the rate of increase in
body weight in WT males (0.51 ± 0.04 g/day) was about
50% faster than that in females (0.34 ± 0.03 g/day). By
postnatal day 50, male and female mice had achieved
slightly over three-quarters of the body weight achieved at
150 days (Fig. 1). Thereafter, the rate of body growth
decreased 6- to 8-fold, but continued to the extent that at
150 days, body weights in WT mice of each gender in Fig.
1 were significantly higher (p < 0.01) than at 50 days of
age. By 150 days of age, body weight was about 3.2 times
higher than wean weight in WT males and 2.8 times in WT
females. Body length reached a plateau in WT mice
between postnatal days 75 and 100 (data not shown).
GHA strongly inhibits early postnatal body weight
At the time of weaning, GHA mice were already 30%
smaller (p < 0.01) than gender-matched, WT mice (Fig. 1,
day 21). At each successive age analyzed, differences in
body weight between GHA and control mice remained
significant (p < 0.01), except for 150 day-old males. Body
weight increased rapidly in GHA mice between weaning
and day 50, as it did in WT mice. GHA strongly inhibited
the rate of increase in body weight during this period of
early, rapid growth, with body weight increasing 0.23 ±
0.02 g/day in GHA males and 0.18 ± 0.2 g/day in GHA
females, about one-half as fast as in WT mice. At day 50,
GHA males weighed 56% less than WT males (Fig. 1), and
GHA females weighed 62% less than WT females. By day
50, male and female transgenic mice had reached only
58.0% and 50.0%, respectively, of the body weight they
Body weights of male and female GHA and WT mice  between 21 and 150 days of age Figure 1
Body weights of male and female GHA and WT mice 
between 21 and 150 days of age Mean body weight (± 
SD) are shown for an average of 12 animals from different lit-
ters at each time point. Differences between GHA and WT 
mice of each gender were significant to at least p < 0.05 at 
each age analyzed.
Age-dependent changes in body weight of GHA mice relative  to WT littermate controls Figure 2
Age-dependent changes in body weight of GHA mice 
relative to WT littermate controls Data are expressed 
as a mean percent of WT values ± SEM. Note the loss of 
effective inhibition of body growth by GHA after 50 days of 
age in both male and female mice.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/6
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were to achieve by day 150 (Fig. 1). By 150 days of age,
GHA and females had attained 3.5 and 3.1 times their
wean weight, respectively.
GHA does not inhibit body weight increases after day 50
Figure 2 shows the body weights of GHA mice expressed
as a percentage of gender-matched, littermate controls.
Intriguingly, the growth inhibitory effect of the GHA
transgene on body weight was lost after day postnatal 50,
and GHA mice grew at a faster rate than WT mice until day
150. By day 150, body weights in GHA males and females
had increased to 93.0 ± 5.4% and 78.9 ± 3.9%, respec-
tively, of WT littermates. In contrast, body length in GHA
mice remained almost constant in relation to WT mice
(males: 84 ± 3%; females: 83 ± 2%) between postnatal
days 25 and 150. These findings highlight the period
between days 21 and 50, a period of rapid increase in
postnatal body weight, as the time when GHA has its most
potent inhibitory effect on body mass. After that period,
GHA fails to inhibit body growth and GHA mice exhibit
catch-up growth.
GHA inhibits the magnitude and velocity of postnatal 
brain growth
There was no statistically significant difference in brain
weight between males and females in either the WT or
GHA mice, so data from both genders were pooled. Brain
weight was significantly smaller in GHA than WT mice at
every age studied (Fig. 3). At an early age, GHA inhibited
brain weight less than body weight. For example, in 25
day-old littermates, average brain weight in GHA mice
was 89.8 ± 4.3% of WT brain weight, while body weight
in GHA mice was 60.2 ± 1.1% that of WT animals in
females and 49.4 ± 6.4% in males. Consistent with the
early inhibition of body weight by GHA, brain weight in
25 day-old littermates was 2.2 ± 0.1% of body weight in
WT and 4.0 ± 0.2% in GHA males and 2.5 ± 0.04% and
3.8 ± 0.1%, respectively, in females. By day 50, after a
period of relatively rapid growth (Fig. 3), the brain
reached 96% of its 150-day size in WT mice and 94% in
GHA mice. Thereafter, the brain grew more slowly in both
WT and GHA mice, being significantly larger (p < 0.05 or
less) than at 50 day by day 150 in WT animals and by day
100 in GHA animals. Thus, most brain growth had
occurred by day 50 in both the control and GHA mice.
GHA inhibits the magnitude and velocity of postnatal 
spinal cord growth
As with the brain, there was no significant gender differ-
ence in spinal cord weight in either control or GHA mice.
GHA mice had significantly smaller spinal cords than WT
mice at each time point analyzed (Fig. 4). In 25 day-old
male and female littermates, average spinal cord weight in
GHA mice was 86.1 ± 1.2% of WT spinal cord weight. At
that early age, spinal cord weight in littermate mice was
0.39 ± 0.04 % of body weight in WT and 0.66 ± 0.04% in
GHA males, and 0.43 ± 0.0% and 0.60 ± 0.02%, respec-
tively, in females. Spinal cord enlargement, like that of the
brain, was more rapid before postnatal day 50 than
afterwards in both WT and GHA mice. On the other hand,
by day 50 the spinal cord had achieved only 70.7% of its
weight at 150 days in WT mice and 75.4% in GHA mice
(Fig. 4). Thus, after postnatal day 50, there was considera-
bly more growth of spinal cord than the brain in both WT
and GHA mice.
Brain weights in GHA and WT mice between 21 and 150  days of age Figure 3
Brain weights in GHA and WT mice between 21 and 
150 days of age. Mean brain weights (± SD) are shown for 
an average of 7 animals (sexes combined) from different lit-
ters at each time point. *p < 0.05; **p < 0.01 Spinal cord weights in GHA and WT mice between 21 and  150 days of age Figure 4
Spinal cord weights in GHA and WT mice between 
21 and 150 days of age. Mean spinal cord weights (± SD) 
are shown for an average of 7 animals (sexes combined) from 
different litters at each time point. *p < 0.05; **p < 0.01BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/6
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GHA has more potent and prolonged inhibitory effects on 
spinal cord than brain growth
Fig. 5 shows brain and spinal cord weight in GHA mice as
a percentage of littermate controls. Of particular interest
was the duration of GHA inhibition on postnatal growth,
one measure of which is the age when the ratio of GHA to
WT values no longer declines. Most inhibition of brain
weight by GHA had occurred by the time of weaning and
little further reduction was observed thereafter, with the
difference between brain weight in the GHA and control
mice remaining constant at about 10%. In contrast, GHA
progressively inhibited spinal cord weight until postnatal
days 125–150, when spinal cord weight in GHA mice had
become 24.5 ± 6.5% less than that of their WT littermates
(Fig. 5). Thus, GHA inhibition of spinal cord growth
relative to littermate controls persisted after day 50, while
brain growth and its inhibition by GHA were minimal
after day 50.
Discussion
GHA differentially inhibits the postnatal growth of the
body, brain and spinal cord. Because GHA antagonizes
the action of GH at the GH receptor, we infer that endog-
enous GH also must differentially influence their growth.
Much of the trophic action of GH on the CNS is probably
mediated by IGF-1, which increases brain and spinal cord
weight largely by increasing white matter [6,7,11,13]. Spi-
nal motor neuron size is also increased postnatally by GH,
but may not depend upon IGF-1 [7].
The contribution of GH to body, spinal cord and brain 
growth
The data presented here imply that GH action is responsi-
ble for at least 10% of the weight of the mature brain and
at least 24% of the weight of the mature spinal cord in the
mouse. These estimates are low, since there is evidence
that GHA does not completely inhibit GH action. Mice
made null for GH by toxin-mediated ablation of soma-
totropes [6,11] showed greater inhibition of brain and
body growth than did GHA mice at the same age in our
study (Fig. 6). Comparisons among GHA, GH null and
GH+ mice [7] mice also provide strong evidence for differ-
ential effects of GH on body, brain and spinal cord
growth. Fig. 6 compares the relative magnitude of GH
effects on growth in these three different mutant models
and includes published data from our laboratories [7,11]
and others [6]. The relative effect of GH perturbation in all
three types of mice in Fig. 6 is the same, being least on
brain weight and most on body weight. While data are
available for the spinal cord only in GHA and GH+ mice,
our findings support a more potent requirement for GH as
a mediator of postnatal spinal cord growth than brain
growth.
An intriguing finding from our study was that GHA mice
exhibited catch-up growth after day 50 by increasing body
growth rates to levels higher than in WT mice. During this
Age-dependent change in brain and spinal cord weight of  GHA mice relative to WT littermate controls Figure 5
Age-dependent change in brain and spinal cord 
weight of GHA mice relative to WT littermate con-
trols Data are expressed as a mean percent of WT values ± 
SEM. Note that GHA continues to reduce spinal cord after 
postnatal day 50, but has little, if any, further effect on brain 
size. First-order regression analyses showed a significant (p < 
0.01) correlation between age and the y-axis values for the 
spinal cord (R = 0.97), but no significant correlation for the 
brain (R = 0.26).
Comparison of body and CNS growth in transgenic mice  with increased and decreased GH action Figure 6
Comparison of body and CNS growth in transgenic 
mice with increased and decreased GH action Mean 
percent changes (± SD) reported for GH+ [7] and GH null 
mice [6,11] are compared with data from the present study. 
The average age of the mice was 65 ± 9 days. Note that the 
rank order of GH and GHA effects on growth is the same in 
all three experimental situations.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/6
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period, body length showed a constant inhibition of 16.2
± 0.03% in all GHA mice. Part of the catch-up growth may
be due to greater increases in adipose tissue mass in GHA
mice, as we have reported previously [14]. It is also possi-
ble that high levels of GHA and inhibition of GH action
in the period of rapid growth between day 25 and 50 elicit
compensatory increases in GH responsiveness either at
the level of GH receptor expression or subsequent intrac-
ellular signal transduction systems.
Does GH play a role in the slowing of postnatal CNS 
growth?
Relative to its weight at birth, the spinal cord grows more
postnatally than does the brain [1,2], and GH stimulates
the enlargement of the spinal cord more than the brain
[7]. Normal postnatal brain growth slows earlier than spi-
nal cord growth (Figs. 3, 4), at the same time as GHA inhi-
bition of their growth diminishes (Fig. 5). Taken together,
these data suggest that cessation of GH action plays a role
in the age-related slowing of brain and spinal cord
enlargement. Three possible mechanisms by which GH
might influence the slowing of CNS growth are: 1) a
decrease in the concentration of circulating GH with age;
2) a decrease in GH responsiveness in the CNS at the level
of the GH receptor or downstream events; or 3), hypothet-
ically, an age-dependent increase in a growth antagonist
that competes with the trophic action of GH on the CNS.
GH responsiveness includes the GH-dependent synthesis
and action of IGF-I, which has powerful trophic effects on
postnatal growth of the brain [6,11,13] and spinal cord
[7]. There is an inverse correlation between serum GHA
and IGF-I concentrations among GHA mice [12].
An age-dependent decrease in the concentration of GH
accessible to all parts of the CNS cannot account for the
observation that GHA continued to inhibit spinal cord
growth well after its action on brain growth was no longer
apparent (Fig. 6). For the same reason, if either an age-
related decrease in GH responsiveness or the action of
some growth antagonist decreased the rate of brain
growth, then such changes must have occurred more
slowly in the spinal cord than in the brain. A decrease in
GH responsiveness is consistent with reports of age-
dependent decreases in GH binding in human brain [15]
and in rat brain and spinal cord [16]. However, Zhai et al.
[16] reported that GH binding began to decline earlier in
the rat spinal cord than in the brain.
Does GH help to maintain CNS size in adult mice?
That GH is responsible for some of the postnatal growth
of the brain and spinal cord suggests that GH could help
to maintain CNS size with age. The dramatic decrease in
circulating GH in older human beings [17] might contrib-
ute to the age-dependent atrophy observed in the spinal
cord [3] and brain [1]. In order to investigate this possibil-
ity in experimental animals, one would ideally want to
allow the CNS to reach its mature size and then to alter the
action of endogenous GH. Transgenic mice expressing an
inducible GHA gene could be used to investigate this pos-
sibility. Such transgenic mice would be useful in studying
not only the effects of GH in the adult mouse CNS, but
also a wide variety of other actions GH may have through-
out the body.
Conclusions
GH plays a significant, but not an exclusive nor uniform
role in postnatal CNS and body growth. Based upon the
actions of GHA, we conclude that GH differentially affects
the magnitude, velocity and duration of postnatal growth
of the brain, spinal cord and body. Early in postnatal life,
GH promotes body enlargement more than CNS growth.
Later, its CNS effects are most obvious in the spinal cord,
which continues to exhibit GH dependence well into
adulthood. Studies using GHA transgenic mice could help
to determine whether the somatotrophic system
contributes to the age-related slowing of CNS growth and
whether it helps to maintain CNS size in adulthood.
Methods
GHA mouse line
Mice hemizygous for the GHA transgene were obtained
from the laboratory of Dr. John J. Kopchick, Edison Bio-
technology Institute, Ohio University. We used line hGH
G120R, which bears a human GH transgene that has an
arginine substituted for the normal glycine at position
120, converting its product to a GH antagonist [12,18].
Body weight as a phenotypic marker for pooled litters of  GHA and WT mice Figure 7
Body weight as a phenotypic marker for pooled lit-
ters of GHA and WT mice No overlap between the 
lower body weights of GHA (left) and heavier WT (right) 
mice was observed for either 50 day-old male (shown here) 
or female mice. The mean body weight (± SD) for GHA 
males at 50 days was 13.4 ± 1.2 g versus 24.2 ± 1.4 g for WT 
males.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/6
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When placed under the control of a mouse metal-
lothionein 1 transcriptional control element, expression
of the GHA transgene lowered serum levels of IGF-I by
approximately 60% and lowered body weights to 60–70%
of WT littermate control weights at three months of age
[18]. Heterozygous transgenic mice on the original
B6SJLF1/J (C57BL/6J × SJL/J) background were bred with
B6SJLF1/J WT mice to provide the animals studied here.
All mice were reared with their littermates and received
normal mouse chow and water containing 25 mM zinc
sulfate to maximize transgene expression. Transgenic
mice were readily distinguished from their gender-
matched, WT littermates between the time of weaning (21
days of age) and day 125. Figure 7 shows the distribution
of body weights in male mice at 50 days of age. A strict
bimodal distribution of body weights was observed for
both males (Fig. 7) and females (data not shown). Each
mouse in a litter was tagged at weaning and its weight and
length recorded at 25-day intervals. Body length measured
from the snout to the proximal end of the tail was used as
an index of skeletal growth. Animal care and euthanasia
were carried out in accordance with the standards of the
University of North Carolina and the American Associa-
tion of Veterinary Medicine.
Tissue collection
At 25-day intervals between ages 25 and 150 days, mice
were injected i.p. with a mixture of xylazine (4 mg/kg) and
ketamine (400 mg/kg), and when fully anesthetized, the
animals were decapitated. The brain of each animal,
including the cerebellum, but not the brainstem, was dis-
sected and weighed on a Mettler semi-micro (P1210) or
micro (H20) balance. The spinal cord was dissected under
a stereomicroscope from the mid-cervical through the
sacral segments, the cauda equina and all other spinal roots
were removed, and the spinal weight was recorded.
Statistical analyses
Means ± s.e.m are presented in the text wherever possible,
while percentages only are used when expressing the per-
cent difference between two unpaired means. Tests of sig-
nificance were performed using Student's paired or
unpaired t-test. Where absolute weights are presented, val-
ues for WT and GHA mice are derived from all litters,
including those containing only WT or GHA mice.
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